Event Details

ESMO Immuno-Oncology Congress 2022 - COM701 & nivolumab ± BMS-986207 in patients with platinum resistant ovarian cancer

December 19, 2022 7:00 AM ET

In these videos, John W. Moroney, M.D., Associate Professor of Gynecologic Oncology in the Dept. of Obstetrics and Gynecology at the University of Chicago and Oladapo Yeku, M.D., Ph.D., FACP, Assistant Professor of Medicine, Harvard Medical School, and Director of Translational Research, Gynecologic Oncology Program, Massachusetts General Hospital, Boston, MA, speak with OncLive about the data they presented at ESMO-IO in platinum resistant ovarian cancer patients treated with COM701 and nivolumab ± BMS-986207

These videos originally published on Onclive.com, and were republished with permission from the publication